News
The people most trusted to deliver are not always the ones invited to shape direction. Executive coach Angela Justice examines why the habits that build a career can eventually limit advancement.
FEATURED STORIES
Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinical Oncology’s annual conference with data from their potential Keytruda rival, alongside Revolution Medicine’s groundbreaking pancreatic cancer candidate and other assets that could reshape patient care.
The tragic tale of TIGIT is well known. However, RIPK1, myc, STING and alpha-synuclein have also left a trail of failed clinical trials, canceled partnerships and sunk investments in their wake.
Analysts homed in on Duchenne muscular dystrophy and myotonic dystrophy type 1 assets during first quarter earnings as major players like REGENXBIO and Novartis as well as Dyne, Wave, Solid and Sarepta near the regulatory finish line.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Job descriptions are the candidate’s first impression of a company. And if that introduction includes exclusionary language, they’re less likely to apply even if they are the perfect fit for the job.
The week started off with a clinical bang for Verona Pharma, Kodiak, AstraZeneca and Daiichi Sankyo with wins in COPD, lung cancer and macular edema respectively.
Mersana unveiled a global collaboration with GSK, which gives GSK the exclusive option to co-develop and commercialize Mersana’s antibody-drug conjugate XMT-2056.
Industry executives often lament the fact that clinical trials take a long time to complete and often fail. BioSpace spoke with Tufts’ Ken Getz about possible reasons and solutions.
A recent report predicts multiple acquisitions are set to be announced in the second half of the year, particularly by companies that have strong revenue streams from COVID-19 products.
Karuna Therapeutics released results from the Phase III EMERGENT-2 trial showing that KarXT, its lead candidate, can strongly reduce symptom severity in schizophrenia patients.
The Inflation Reduction Act, which is expected to have wide-ranging implications for the pharmaceutical industry, will still need to go to the House of Representatives.
Results from two Amgen studies on Lumakras for lung cancer showed its ability to slow disease progression, although combining it with immunotherapy increased the risk for TRAEs.
Pfizer announced Monday that it is acquiring the hematology-focused company for $5.4 billion in order to bolster its presence in the multi-billion dollar rare disease market.
If the FDA ultimately votes to approve Eli Lilly’s donanemab or Eisai’s lecanemab – both anti-amyloid beta (Aβ) antibodies – what impact will it make on Alzheimer’s disease?